Introduction

Did you know that the Pharmaceutical and Life Sciences Global Capability Centres (GCCs) Market is projected to grow from USD 26.96 billion in 2024 to USD 92.38 billion by 2032, at a strong CAGR of 14.88%? These centres are no longer just back-office support units—today, they are becoming innovation hubs, powering R&D, regulatory compliance, and digital transformation. But what makes them so critical for the future of healthcare? With rising demand for personalized medicine, digital-first operations, and faster drug development, GCCs are playing a central role in shaping global pharma strategies.

Key Players

When you think of leaders in this transformation, which companies come to mind first—Pfizer, Novartis, or Sanofi? All three, along with others like Merck, Roche, AstraZeneca, and Johnson & Johnson, are heavily investing in GCCs across regions like India, the U.S., and Europe. For example, Pfizer’s GCC in Chennai now drives AI-driven regulatory automation, while Novartis leverages its Indian centres for advanced analytics and clinical trial optimization.

Can you see how these companies are blending technology with medicine to accelerate innovation?

Segmentation

Now, where are the biggest opportunities within GCCs? By service, IT and digital transformation lead with 38.6% share, showing how vital AI, cloud, and data analytics have become. By function, R&D dominates with 36.8%, reflecting the industry’s push toward faster drug discovery and clinical trials.

And when it comes to organizational models, captive centres hold 58.3% share—wouldn’t you agree that pharma giants prefer full control over sensitive data and compliance?

About Us

In the fast-paced business biospheres, businesses need to constantly evolve to grow and stay relevant. At S&S Insider, we believe in adopting a data-oriented approach to aid organizations be familiar with the nerve of the industry.

E-mail ID – Info@snsinsider.com

Contact No - +1-415-230-0044